Skip to content Norwegian Medical Products Agency Norwegian Medical Products Agency

Guidance for submission of Norwegian translations of direct healthcare professional communication (DHPC)



Direct healthcare professional communication (DHPC) is communication regarding important safety information delivered directly to individual healthcare professionals by a marketing authorisation holder.

Page contents

    The preparation of DHPCs involves cooperation between the marketing authorisation holder (MAH) and the Norwegian Medical Products Agency (NOMA). Agreement between these two parties should be reached before a DHPC is issued by the marketing authorisation holder. The agreement will cover both the content of the DHPC and the communication plan including the intended recipients, the timetable and the channels for disseminating the DHPC (See more information in Good Vigilance Practices - module XV).

    Where there are several marketing authorisation holders of the same active substance and/or a class of products for which a DHPC is to be issued, a single consistent message should be delivered to healthcare professionals.

    Submission of Norwegian translations to NOMA

    The following documents should be sent to NOMA by email to

    • The English version of the DHPC
    • The Norwegian translation in clear and concise language adjusted to the target group
    • Suggestions for recipients of the DHPC

    It is not necessary to send DHPCs to the Regional Pharmacovigilance Centers (RELIS).

    Other communication

    Information letters regarding drug shortage should be sent to

    Information letters regarding quality defect/technical issues should be sent to

    Comments from NOMA

    NOMA will review the DHPCs and provide comments to content and target groups, but does not issue an approval per se.

    Standard labeling

    DHPCs should be labeled with NOMAs logo for safety ​information​​.

    Standard text

    ​In the DHPC-letter, there should be a standard sentence calling for reporting suspected adverse reactions through the national reporting system.

    Standard text for reporting adverse reactions (for medicinal products without black triangle)

    Oppfordring om å melde mistenkte bivirkninger

    Melding av mistenkte bivirkninger etter godkjenning av legemidlet er viktig. Det gjør det mulig å overvåke forholdet mellom nytte og risiko for legemidlet kontinuerlig. 

    Helsepersonell oppfordres til å melde nye, uventede og alvorlige mistenkte bivirkninger på elektronisk meldeskjema:​

    Standard text for reporting adverse reactions (for medicinal products without black triangle)​

    Oppfordring om å melde mistenkte bivirkninger

    ▼ Dette legemidlet er underlagt særlig overvåking for å oppdage ny sikkerhetsinformasjon så raskt som mulig.

    Helsepersonell oppfordres til å melde enhver mistenkt bivirkning. Dette gjøres via meldeskjema som finnes på nettsiden til Direktoratet for medisinske produkter:​​​

    Black triangle▼

    DHPCs regarding a medicinal product under additional monitoring must be labeled with the black triangle ▼. The triangle should be placed in front of the product name (▼product name) in the start of the letter, as applicable. 



    DHPCs can be disseminated to community and hospital pharmacies by e-mail. A list of the pharmacies e-mail addresses can be retrieved from Felleskatalogen. To receive the lists, send an e-mail to​ with the subject field "E-mail pharmacy for dissemination of DHPC".

    The e-mail disseminated to the pharmacies should contain the text "Safety information in collaboration with the Norwegian Medical Products Agency" in the subject field. The DHPC is attached to the e-mail in pdf format.

    General practicioners

    DHPC letters to general practitioners are distributed exclusively via electronic channels, this is handled by the Norwegian Medical Products Agency (see section Publication). ​

    Pharmaceutical companies do not need to distribute the letter to GPs/GPs on paper.​

    Other groups of health personnell

    DHPCs to other groups of health professionals must be sent by mail.


    NOMA publishes all DHPCs in an archive. The final version of the letter should be sent to NOMA prior to distribution for publication. 

    NoMA will also notify prescribing physicians of a new DHPC-letter through the patient journal (EPJ)

    The Norwegian Pharmaceutical Compendium (Felleskatalogen) will publish the DHPCs intergrated into safety alerts from NOMA. Felleskatalogen will collect the DHPCs from NOMAs website (the MAH does not have to send the letter to Felleskatalogen). ​

    Contact us

    Unit for better use of medicines

    +47 22 89 77 00